Merck & Co. (MRK) announced Sunday that preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab, its antibody therapy targeting PD-1, in patients with advanced melanoma, was presented at ASCO.
Merck & Co. gapped open higher Monday and is now up 1.90 at $48.60. The stock is challenging the highs of the year, trading at over a 1-month high.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.